 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
0 News |  |
| 12» |
- | SCB-2019 / Sichuan Clover Biopharma
Journal: Indirect effectiveness of a novel SAR-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: a cluster randomised analysis. (Pubmed Central) - Sep 20, 2024
P2/3
SCB-2019 demonstrated bias-corrected indirect effectiveness against SARS-CoV-2 infection among HHC, even at a modest coverage level in the household (approximately 25%). Further research into the indirect effects of SARS-CoV-2 vaccines is needed to optimize the impact of limited doses in low and middle-income settings.
- ||| SCB-2019 / Sichuan Clover Biopharma, Comirnaty (tozinameran) / Pfizer, BioNTech
P3 data, Journal, Real-world evidence, Real-world: Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice. (Pubmed Central) - Jul 11, 2024
P3
Protein, adenovirus-vector or mRNA vaccine boosters were equally well tolerated and immunogenic against ancestor SARS-CoV-2 and Omicron sub-lineages in fully primed adults with 0-2 prior boosters. BNT162b induced the highest immune responses but also the most rapid waning of antibodies 3?months after vaccination.
- || SCB-219M / Sichuan Clover Biopharma
Trial completion date, Trial primary completion date: A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT) (clinicaltrials.gov) - May 7, 2024
P1, N=76, Recruiting, Sponsor: Sichuan Clover Biopharmaceuticals, Inc.
BNT162b induced the highest immune responses but also the most rapid waning of antibodies 3?months after vaccination. Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- SCB-219M / Sichuan Clover Biopharma
A phase I clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and preliminary efficacy of SCB-219M in patients with chemotherapy-induced thrombocytopenia (CIT): An interim analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4721;
P1
Accordingly, a Phase Ib trial evaluating repeated dosing of SCB-219M is planned to initiate in 2024. Clinical trial information: NCT05426369.
- || Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Retrospective data, Review, Journal: Efficacy of adjuvant-associated COVID-19 vaccines against SARS-CoV-2 variants of concern in randomized controlled trials: A systematic review and meta-analysis. (Pubmed Central) - Feb 20, 2024
Notably, with the exception of the aluminum-adjuvanted vaccine, the other ACVs had moderate to high efficacy against the SARS-CoV-2 variant. This raises concerns about the effectiveness of ACVs booster vaccinations against Omicron.
- | SCB-2019 / Sichuan Clover Biopharma
Journal: SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines. (Pubmed Central) - Jan 15, 2024
No vaccine-related serious adverse events were reported. Heterologous SCB-2019 boosting was well tolerated and elicited neutralizing responses against all tested SARS-COV-2 viruses including Omicron BA.1, BA.2, BA.4, BA.5, BF.7, BQ.1.1.3, and XBB1.5 sub-lineages that were non-inferior to homologous boosting with CoronaVac or Vaxzevria, but not homologous Comirnaty booster.
- | SCB-2019 / Sichuan Clover Biopharma
Journal: Boosting with adjuvanted SCB-2019 elicits superior Fc?-receptor engagement driven by IgG3 to SARS-CoV-2 spike. (Pubmed Central) - Jan 6, 2024
Moreover, from day 15 after vaccination, Group 3 exhibited higher IgG3 and Fc?R binding across variants of concerns, including Omicron and its subvariants, compared to the ChAdOx1-boosted individuals. Overall, this highlights the potential of SCB-2019 as a cost-efficient boosting regimen effective across variants of concerns.
- || Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Review, Journal: Vaccination is the most effective and best way to avoid the disease of COVID-19. (Pubmed Central) - Sep 3, 2023
Among the vaccines that stimulate the host's immune system with the help of DNA are: undergoing Phase 2/3 trials including INO-4800 (International Vaccine Institute; Inovio Pharmaceuticals), Symvivo, Canada-COVID19 (AnGes, Inc.); GX-19 (Genexine, Inc.). BNT162b2
- || SCB-2019 / Sichuan Clover Biopharma
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults (clinicaltrials.gov) - Aug 25, 2023
P3, N=0, Withdrawn, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
BNT162b2 N=600 --> 0 | Trial completion date: Sep 2024 --> Aug 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2024 --> Aug 2023
- ||||||| SCB-2019 / Sichuan Clover Biopharma
Trial completion, Trial completion date: Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults (clinicaltrials.gov) - Aug 24, 2023
P3, N=1831, Completed, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
N=600 --> 0 | Trial completion date: Sep 2024 --> Aug 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2024 --> Aug 2023 Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Jun 2023
- | SCB-2019 / Sichuan Clover Biopharma, CoronaVac / Sinovac, Bio Farma Indonesia
Journal: Superior boosting of neutralizing titers against Omicron SARS-CoV-2 variants by heterologous SCB-2019 vaccine vs a homologous booster in CoronaVac-primed adults. (Pubmed Central) - Jul 13, 2023
Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Jun 2023 Boosting CoronaVac-immunized adults with full or half doses of SCB-2019 was well tolerated with superior immunogenicity than homologous boosting, particularly against newly emerged variants, supporting use of SCB-2019 for booster vaccination.
- |||||||||| SCB-2019 / Sichuan Clover Biopharma
New P3 trial: Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults (clinicaltrials.gov) - Jul 3, 2023
P3, N=600, Not yet recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
- ||| SCB-2019 / Sichuan Clover Biopharma, SCB-2020S / Sichuan Clover Biopharma
Trial completion, Trial completion date, Trial primary completion date: Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults (clinicaltrials.gov) - Jul 3, 2023
P1, N=153, Completed, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Boosting CoronaVac-immunized adults with full or half doses of SCB-2019 was well tolerated with superior immunogenicity than homologous boosting, particularly against newly emerged variants, supporting use of SCB-2019 for booster vaccination. Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Apr 2023 | Trial primary completion date: Sep 2023 --> Sep 2022
- ||||||| SCB-2019 / Sichuan Clover Biopharma
Trial completion: SPECTRA: A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (clinicaltrials.gov) - Jun 29, 2023
P2/3, N=31454, Completed, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Apr 2023 | Trial primary completion date: Sep 2023 --> Sep 2022 Active, not recruiting --> Completed
- | SCB-2019 / Sichuan Clover Biopharma
Journal: Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents. (Pubmed Central) - Jun 28, 2023
P2/3
SCB-2019 vaccine was highly immunogenic against SARS-CoV-2 prototype and variants in adolescents, especially in those with evidence of prior exposure, with comparable immunogenicity to young adults. Clinical trial registration: EudraCT 2020-004272-17; ClinicalTrials.gov NCT04672395.
- | SCB-2019 / Sichuan Clover Biopharma
New P3 trial, Real-world evidence, Real-world: Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes. (clinicaltrials.gov) - Apr 13, 2023
P3, N=760, Active, not recruiting, Sponsor: D'Or Institute for Research and Education
- rilunermin alfa (SCB-313) / Sichuan Clover Biopharma
Enrollment change, Trial termination, Trial primary completion date: A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov) - Apr 12, 2023
P1, N=10, Terminated, Sponsor: Sichuan Clover Biopharmaceuticals, Inc.
Clinical trial registration: EudraCT 2020-004272-17; ClinicalTrials.gov NCT04672395. N=20 --> 10 | Recruiting --> Terminated | Trial primary completion date: Feb 2022 --> May 2022; terminated
- | SCB-2019 / Sichuan Clover Biopharma
Journal: Impact of vaccination with SCB-2019 COVID-19 vaccine on transmission of SARS-CoV-2 infection: a household contact study in the Philippines. (Pubmed Central) - Apr 5, 2023
N=20 --> 10 | Recruiting --> Terminated | Trial primary completion date: Feb 2022 --> May 2022; terminated In this prospective household contact study vaccination with SCB-2019 reduced SARS-CoV-2 transmission compared with placebo in households and in household members independently of whether or not index cases were symptomatic.
- ||| SCB-2019 / Sichuan Clover Biopharma
P2/3 data, Clinical Trial,Phase III, Journal: Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study. (Pubmed Central) - Mar 28, 2023
P2/3
SCB-2019 administered as a 2-dose series has an acceptable safety profile. No safety concerns were identified during the 6-month follow-up after the primary vaccination.
- || SCB-2019 / Sichuan Clover Biopharma
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age (clinicaltrials.gov) - Mar 24, 2023
P2/3, N=0, Withdrawn, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
No safety concerns were identified during the 6-month follow-up after the primary vaccination. N=3820 --> 0 | Trial completion date: Jul 2024 --> Dec 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2024 --> Dec 2022
- ||||| SCB-2019 / Sichuan Clover Biopharma
Enrollment closed, Trial completion date, Trial primary completion date: Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults (clinicaltrials.gov) - Mar 22, 2023
P3, N=1831, Active, not recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
N=3820 --> 0 | Trial completion date: Jul 2024 --> Dec 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2024 --> Dec 2022 Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Feb 2024 | Trial primary completion date: Mar 2023 --> Jun 2023
- ||| SCB-2019 / Sichuan Clover Biopharma, adjuvant CpG 1018 / Dynavax
P2/3 data, Journal: Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-na (Pubmed Central) - Mar 6, 2023
P2/3
Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Feb 2024 | Trial primary completion date: Mar 2023 --> Jun 2023 A single dose of SCB-2019 was immunogenic in SARS-CoV-2-exposed individuals, whereas two doses were required to induce immune response in SARS-CoV-2-na
- || SCB-2019 / Sichuan Clover Biopharma, SCB-2020S / Sichuan Clover Biopharma
Enrollment closed: Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults (clinicaltrials.gov) - Oct 19, 2022
P1, N=153, Active, not recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
A single dose of SCB-2019 was immunogenic in SARS-CoV-2-exposed individuals, whereas two doses were required to induce immune response in SARS-CoV-2-na Recruiting --> Active, not recruiting
- |||| SCB-2019 / Sichuan Clover Biopharma
Trial completion date, Trial primary completion date: Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults (clinicaltrials.gov) - Oct 17, 2022
P3, N=1822, Recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Recruiting --> Active, not recruiting Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Mar 2023
- || SCB-2019 / Sichuan Clover Biopharma
Clinical, Journal: Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine. (Pubmed Central) - Oct 1, 2022
SCB-2019 dose-dependently induced immune responses against wild-type SARS-CoV-2, which persisted up to day 184. Neutralizing antibodies were cross-reactive against 3 of the most prevalent VoCs.
- || SCB-2019 / Sichuan Clover Biopharma
P2 data, Journal: Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study. (Pubmed Central) - Sep 1, 2022
P2
Boosting ChAdOx1-S-primed adults with SCB-2019 induced higher levels of antibodies against a wild-type strain and SARS-CoV-2 variants than a homologous ChAdOx1-S booster, with the highest responses being with the 30-μg SCB-2019 + CpG + aluminium hydroxide formulation. NCT05087368.
- ||||| SCB-2019 / Sichuan Clover Biopharma
Enrollment closed, Trial completion date: SPECTRA: A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (clinicaltrials.gov) - Aug 29, 2022
P2/3, N=31454, Active, not recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
NCT05087368. Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Apr 2023
- ||||| SCB-2019 / Sichuan Clover Biopharma
Trial initiation date: Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age (clinicaltrials.gov) - Aug 24, 2022
P2/3, N=3820, Not yet recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Apr 2023 Initiation date: Jul 2022 --> Jan 2023
- | SCB-2019 / Sichuan Clover Biopharma, Comirnaty (tozinameran) / Pfizer, BioNTech
New P3 trial: An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens (clinicaltrials.gov) - Jul 23, 2022
P3, N=360, Not yet recruiting, Sponsor: D'Or Institute for Research and Education
- |||||| SCB-2019 / Sichuan Clover Biopharma
Enrollment open: Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults (clinicaltrials.gov) - Jul 12, 2022
P3, N=1272, Recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Initiation date: Jul 2022 --> Jan 2023 Not yet recruiting --> Recruiting
- | SCB-2019 / Sichuan Clover Biopharma
Journal: The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2. (Pubmed Central) - Jun 29, 2022
Not yet recruiting --> Recruiting No abstract available
- || SCB-2019 / Sichuan Clover Biopharma
P2 data, Journal: Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. (Pubmed Central) - Jun 29, 2022
Previous exposure to SARS-CoV-2 decreased the risk and severity of subsequent COVID-19 infection, even against newly emerging variants. Protection is further enhanced by one or two doses of SCB-2019.
- ||| SCB-219M / Sichuan Clover Biopharma
Enrollment open: A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT) (clinicaltrials.gov) - Jun 29, 2022
P1, N=76, Recruiting, Sponsor: Sichuan Clover Biopharmaceuticals, Inc.
Protection is further enhanced by one or two doses of SCB-2019. Not yet recruiting --> Recruiting
- ||| SCB-219M / Sichuan Clover Biopharma
New P1 trial: A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT) (clinicaltrials.gov) - Jun 22, 2022
P1, N=76, Not yet recruiting, Sponsor: Sichuan Clover Biopharmaceuticals, Inc.
- ||| SCB-2019 / Sichuan Clover Biopharma, SCB-2020S / Sichuan Clover Biopharma
Enrollment open: Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults (clinicaltrials.gov) - Jun 21, 2022
P1, N=152, Recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Clinical, Retrospective data, Review, Journal: Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. (Pubmed Central) - May 25, 2022
Booster vaccination is more effective against Delta and Omicron variants. mRNA vaccines seem to have higher VE against Alpha, Beta, Gamma, and Delta variants over others.
- | SCB-2019 / Sichuan Clover Biopharma
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases (clinicaltrials.gov) - May 25, 2022
P3, N=1, Terminated, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
mRNA vaccines seem to have higher VE against Alpha, Beta, Gamma, and Delta variants over others. N=300 --> 1 | Trial completion date: Dec 2022 --> May 2022 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2022 --> Mar 2022; The study was early terminated considering the inability to enroll the required study population.
- ||||| SCB-2019 / Sichuan Clover Biopharma
Trial initiation date: Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults (clinicaltrials.gov) - May 20, 2022
P3, N=1272, Not yet recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
N=300 --> 1 | Trial completion date: Dec 2022 --> May 2022 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2022 --> Mar 2022; The study was early terminated considering the inability to enroll the required study population. Initiation date: Mar 2022 --> Jun 2022
- || rilunermin alfa (SCB-313) / Sichuan Clover Biopharma
Trial completion, Enrollment change: A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion (clinicaltrials.gov) - May 6, 2022
P1, N=14, Completed, Sponsor: Sichuan Clover Biopharmaceuticals, Inc.
Initiation date: Mar 2022 --> Jun 2022 Active, not recruiting --> Completed | N=25 --> 14
- || rilunermin alfa (SCB-313) / Sichuan Clover Biopharma
Trial completion: Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites (clinicaltrials.gov) - May 6, 2022
P1, N=13, Completed, Sponsor: Sichuan Clover Biopharmaceuticals, Inc.
Active, not recruiting --> Completed | N=25 --> 14 Active, not recruiting --> Completed
- ||||| SCB-2019 / Sichuan Clover Biopharma
Trial initiation date: Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age (clinicaltrials.gov) - Apr 28, 2022
P2/3, N=3820, Not yet recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Active, not recruiting --> Completed Initiation date: Mar 2022 --> Jul 2022
- | SCB-420 (aflibercept biosimilar) / Sichuan Clover Biopharma
Enrollment change, Trial withdrawal: Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Apr 19, 2022
P1, N=0, Withdrawn, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Initiation date: Mar 2022 --> Jul 2022 N=20 --> 0 | Not yet recruiting --> Withdrawn
- ||| SCB-2019 / Sichuan Clover Biopharma
Enrollment closed, Trial completion date: Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China (clinicaltrials.gov) - Mar 10, 2022
P2, N=766, Active, not recruiting, Sponsor: Zhejiang Clover Biopharmaceuticals, Inc.
N=20 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Nov 2022
- SCB-313 / Sichuan Clover Biopharma
First-in-human (FIH) phase I studies of SCB-313, a novel TNF-related apoptosis-inducing ligand TRAIL-Trimer™ fusion protein, for treatment of patients (pts) with malignant ascites (MA) (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6642;
P1
Measurable ascites flow rate decrease were observed at all dose- levels. These data support further development of SCB-313 for pts with MA.
- || SCB-420 (aflibercept biosimilar) / Sichuan Clover Biopharma
Trial initiation date: Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Mar 9, 2022
P1, N=20, Not yet recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
These data support further development of SCB-313 for pts with MA. Initiation date: Aug 2021 --> Apr 2022
- |||||| SCB-2019 / Sichuan Clover Biopharma
Enrollment open, Enrollment change: SPECTRA: A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (clinicaltrials.gov) - Feb 24, 2022
P2/3, N=30000, Recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Initiation date: Aug 2021 --> Apr 2022 Not yet recruiting --> Recruiting | N=22000 --> 30000
- ||| SCB-2019 / Sichuan Clover Biopharma
Trial completion, Trial completion date, Trial primary completion date: SCB-2019 as COVID-19 Vaccine (clinicaltrials.gov) - Feb 18, 2022
P1, N=166, Completed, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Not yet recruiting --> Recruiting | N=22000 --> 30000 Active, not recruiting --> Completed | Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
- ||| SCB-2019 / Sichuan Clover Biopharma
Trial completion, Trial completion date, Trial primary completion date: CLO-SCB-2019-002: Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19. (clinicaltrials.gov) - Feb 11, 2022
P1, N=137, Completed, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Active, not recruiting --> Completed | Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Oct 2021 Recruiting --> Completed | Trial completion date: Sep 2023 --> Dec 2021 | Trial primary completion date: May 2023 --> Nov 2021
- ||| SCB-2019 / Sichuan Clover Biopharma, SCB-2020S / Sichuan Clover Biopharma
New P1 trial: Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults (clinicaltrials.gov) - Feb 7, 2022
P1, N=152, Not yet recruiting, Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
- || SCB-2019 / Sichuan Clover Biopharma
P2 data, Clinical Trial,Phase III, Journal: Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. (Pubmed Central) - Feb 4, 2022
P2/3
Recruiting --> Completed | Trial completion date: Sep 2023 --> Dec 2021 | Trial primary completion date: May 2023 --> Nov 2021 Two doses of SCB-2019 vaccine plus CpG and alum provides notable protection against the entire severity spectrum of COVID-19 caused by circulating SAR-CoV-2 viruses, including the predominating delta variant.